Full Press Release Details
immatics to Receive Support From Pfizer for its Pivotal Phase III Study (IMPRINT) With IMA901, a Therapeutic Vaccine for Advanced Renal Cell Cancer Patients.
IMTX
immatics to Receive Support From Pfizer for its Pivotal Phase III Study (IMPRINT) With IMA901, a Therapeutic Vaccine for Advanced Renal Cell Cancer Patients
Key Takeaway: immatics to Receive Support From Pfizer for its Pivotal Phase III Study (IMPRINT) With IMA901, a Therapeutic Vaccine for Advanced Renal Cell Cancer Patients